Development of Cagrilintide, a Long-Acting Amylin Analogue
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
) and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rybelsus is an oral form of semaglutide, a modified GLP-1 analog in which the native peptide has been engineered for both enzymatic stability and albumin binding: specifically, an Aib (α-aminoisobutyric acid) substitution at position 8 to resist DPP-4 degradation and an attached C18 fatty diacid chain at lysine 26 (via a spacer) to promote reversible albumin binding and extend half-life [63].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [63]
In the citing paper
“Cagrilintide acts on amylin and calcitonin receptors within the area of the postrema and nucleus tractus solitarius, lowering food intake through both homeostatic and hedonic mechanisms. It slows gastric emptying, suppresses postprandial glucagon secretion, and reduces appetite via central hypothalamic pathways [63].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [63]
In the citing paper
“Amylin may promote weight reduction and increase sensitivity to leptin in patients with obesity.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [169]
In the citing paper
“Cagrilintide is a long-acting amylin analogue [169,164].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [169]
In the citing paper
“A closely related long-acting amylin analogue, cagrilintide has recently been shown to reduce body weight by about 10% at doses of 2.4 mg and 4.5 mg injected subcutaneously once weekly during a 26-week study in overweight and obese individuals [41,42].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [41]
Citations
Cites
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Self-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
In Vivo Seeding and Cross-Seeding of Localized Amyloidosis
Oskarsson, M. E., Paulsson, J. F., Schultz, S. W., Ingelsson, M., Westermark, P., & Westermark, G. T. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.11.016 · Cited by 281
Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor
Liang, Y.-L., Khoshouei, M., Deganutti, G., Glukhova, A., Koole, C., Peat, T. S., Radjainia, M., Plitzko, J. M., Baumeister, W., Miller, L. J., et al. (2018) · Nature · doi:10.1038/s41586-018-0535-y · Cited by 238
Lutz, T., Mollet, A., Rushing, P., Riediger, T., & Scharrer, E. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801664 · Cited by 223
Research works printed but not linked: 2
- Srinivasan A., 2020, J. Musculoskelet. Neuronal Interact., 20, 600
- World Health Organization. International nonproprietary names for pharmaceutical substances (INN), Drug Information, 2020; Vol. 34, pp 263–301. https://www.who.int/docs/default-source/international-nonproprietary-names-(inn)/pl123.pdf (accessed 9 Feb 2021).
Cited by
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238
Recent advances in the development of therapeutic peptides
Fetse, J., Kandel, S., Mamani, U., & Cheng, K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.003 · Cited by 179
Derivatization with fatty acids in peptide and protein drug discovery
Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 153
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
A structural basis for amylin receptor phenotype
Cao, J., Belousoff, M. J., Liang, Y.-L., Johnson, R. M., Josephs, T. M., Fletcher, M. M., Christopoulos, A., Hay, D. L., Danev, R., Wootten, D. L., et al. (2022) · Science · doi:10.1126/science.abm9609 · Cited by 99
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Mediators of Amylin Action in Metabolic Control
Boyle, C. N., Zheng, Y., & Lutz, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082207 · Cited by 67
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Artasensi, A., Mazzolari, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2023) · Molecules · doi:10.3390/molecules28073094 · Cited by 74
From lead to market: chemical approaches to transform peptides into therapeutics
Gare, C. L., White, A. M., & Malins, L. R. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.01.009 · Cited by 67
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000513 · Cited by 46
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins
Kotliar, I. B., Lorenzen, E., Schwenk, J. M., Hay, D. L., & Sakmar, T. P. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000180 · Cited by 56
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
Diabetes: a review of its pathophysiology, and advanced methods of mitigation
Gupta, S., Sharma, N., Arora, S., & Verma, S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2333440 · Cited by 53
Long-acting amylin analogues for the management of obesity
Mathiesen, D. S., Bagger, J. I., & Knop, F. K. (2022) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000716 · Cited by 36
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“It slows gastric emptying, suppresses postprandial glucagon secretion, and reduces appetite via central hypothalamic pathways [63].”
Larsen, A. T., Mohamed, K. E., Sonne, N., BREDTOFT, E.-M., Andersen, F., Karsdal, M. A., & Henriksen, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113842 · Cited by 43
Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264974 · Cited by 36
Self-citationAmylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
Walker, C. S., Aitken, J. F., Amarsingh, G. V., Zhang, S., & Cooper, G. J. S. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01125-9 · Cited by 40
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Linking hIAPP misfolding and aggregation with type 2 diabetes mellitus: a structural perspective
Hassan, S., White, K., & Terry, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211297 · Cited by 38
Nielsen, J. C. F., Hjørringgaard, C. U., Nygaard, M. M., Wester, A., Elster, L., Porsgaard, T., Mikkelsen, R. B., Rasmussen, S. A., Madsen, A. N., Schlein, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00417 · Cited by 34
Self-citationGoldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
Self-citationCagrilintide lowers bodyweight through brain amylin receptors 1 and 3
Carvas, A. O., Leuthardt, A. S., Kulka, P., Lommi, G., Hassan, S., Coester, B., Lundh, S. H., Pers, T. H., Secher, A. L., Raun, K., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105836 · Cited by 29
Self-citationRecent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
Mathiesen, D. S., Lund, A., Holst, J. J., Knop, F. K., Lutz, T. A., & Bagger, J. I. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1261 · Cited by 23
Structural insight into selectivity of amylin and calcitonin receptor agonists
Cao, J., Belousoff, M. J., Gerrard, E. J., Danev, R., Fletcher, M. M., Maso, E. D., Schreuder, H., Lorenz, K., Evers, A., Tiwari, G., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01393-4 · Cited by 24
An Insight into the Combat Strategies for the Treatment of Type 2 Diabetes Mellitus
Chawla, G., Pradhan, T., & Gupta, O. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230517113936 · Cited by 20
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
An updated patent review of GLP-1 receptor agonists (2020-present)
Lu, W., Zhou, Z., Jiang, N., & Han, J. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2274905 · Cited by 17
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
Cao, J., Belousoff, M. J., Johnson, R. M., Keov, P., Mariam, Z., Deganutti, G., Christopoulos, G., Hick, C. A., Reedtz‐Runge, S., Glendorf, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58680-y · Cited by 18
Self-citationLarsen, A. T., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175837 · Cited by 16
CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure
Jacobsen, J. M., Halling, J. F., Blom, I., Moreno Martinez, J., Hald, B., Pedersen, K., Fels, J. J., Snitker, S., Secher, A., Lundh, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01324-8 · Cited by 15
Self-citationThe effects of anti‐obesity medications on bone metabolism: A critical appraisal
Anastasilakis, A. D., Paccou, J., Palermo, A., & Pοlyzos, S. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16541 · Cited by 21
Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue
Munch, H. K., Just, R., Mathiesen, J. M., Eriksson, P.-O., Villadsen, J. S., Vestergaard, B., Deryabina, M. A., Demmer, O., Skarbaliene, J., Hamprecht, D. W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01185 · Cited by 15
Buse, J. B., BAJAJ, H. S., Dalskov, S., Donaldson, L., Duus, H. H. H., Fabricius, T. W., Haluzík, M., Lingvay, I., Pedersen, S. D., Pratley, R. E., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00125-7 · Cited by 22
Keov, P., Christopoulos, G., Hick, C. A., Glendorf, T., Ballarín-González, B., Wootten, D. L., & Sexton, P. M. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.123.000865 · Cited by 15
NN1213 – A Potent, Long-Acting, and Selective Analog of Human Amylin
Dahl, K., Raun, K., Hansen, J. L., Poulsen, C., de la Cour, C. D., Clausen, T. R., Hansen, A. M. K., John, L. M., Plesner, A., Sun, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00022 · Cited by 17
Self-citationG protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
The story of amylin: from physiology to therapy
Secher, A., Lutz, T. A., & Raun, K. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01465-4 · Cited by 16
Self-citationBoianelli, A., Nordell, P., Earl, J., Naylor, J., Hornigold, D. C., Jansson‐Löfmark, R., & Sundqvist, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101310 · Cited by 15
Lee, S. M. (2021) · Biomolecules · doi:10.3390/biom11091364 · Cited by 12
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Central nervous system pathways targeted by amylin in the regulation of food intake
Hankir, M. K., & Foll, C. L. (2024) · Biochimie · doi:10.1016/j.biochi.2024.10.012 · Cited by 14
Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors
Piper, N. B. C., Whitfield, E. A., Stewart, G. D., Xu, X., & Furness, S. G. B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115115 · Cited by 11
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
Ludwig, M. Q., Coester, B., Gordian, D., Hassan, S., Tomlinson, A. J., Toure, M. H., Christensen, O. P., Moltke-Prehn, A., Brown, J. M., Rausch, D. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632726 · Cited by 10
Self-citationThe processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity
Mazzini, G., Foll, C. L., Boyle, C. N., Garelja, M. L., Zhyvoloup, A., Miller, M. E. T., Hay, D. L., Raleigh, D. P., & Lutz, T. A. (2024) · Biophysical Chemistry · doi:10.1016/j.bpc.2024.107201 · Cited by 10
Variable CGRP family peptide signaling durations and the structural determinants thereof
Babin, K. M., Gostynska, S. E., Karim, J. A., & Pioszak, A. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116235 · Cited by 10
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir, M. K., & Lutz, T. A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03047-3 · Cited by 16
Role of amylin in feeding and satiation
Lutz, T. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110587 · Cited by 12
Analysis of Sheep and Goat IAPP Provides Insight into IAPP Amyloidogenicity and Cytotoxicity
Miller, M. E. T., Li, M., Baghai, A., Peetz, V. H., Zhyvoloup, A., & Raleigh, D. P. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00470 · Cited by 10
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Zong, L., Zhang, Z., Li, X., Jie, J., Jiang, X., Wang, Z., Liu, W., Shen, X., Feng, X., Huang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01120 · Cited by 10
Amylin receptor subunit interactions are modulated by agonists and determine signaling
Gostynska, S. E., Karim, J. A., Ford, B. E., Gordon, P. H., Babin, K. M., Inoue, A., Lambert, N. A., & Pioszak, A. A. (2025) · Science Signaling · doi:10.1126/scisignal.adt8127 · Cited by 11
Yamauchi, T., Becker, N., Hagemann, C. A., Huang, K.-C., Kiyosue, A., Lim, S., Onishi, Y., Kosuvaripalli, A., Takano, T., & Ishigaki, Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00402-4 · Cited by 12
Pharmacotherapy for chronic obesity management: a look into the future
Abdel-Malek, M., Yang, L., & Miras, A. D. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03237-4 · Cited by 14
An update on current type 2 diabetes mellitus (T2DM) druggable targets and drugs targeting them
Uniyal, P., Panwar, S., Bhatt, A., Marianesan, A. B., Kumar, R., Singh, T. G., Tyagi, Y., Bushi, G., Gaidhane, A. M., & Kumar, B. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11149-y · Cited by 11
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Shaping the future of cardiometabolic innovation: advances and opportunities
Clemmensen, C., Gerhart‐Hines, Z., Schwartz, T. W., Zierath, J. R., & Sakamoto, K. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01343-5 · Cited by 7
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
Rejili, M. S., Hussain, M. S., Khan, Y., Haouala, F., Ganesan, S., Sahoo, S., Pal, A., & Arora, V. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107563 · Cited by 7
Regulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
Wilbs, J., Raavé, R., Boswinkel, M., Glendorf, T., Rodriguez, D. J., Fernandes, E. F. A., Heskamp, S., Bjørnsdottir, I., & Gustafsson, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02073 · Cited by 7
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2026) · Peptides · doi:10.1016/j.peptides.2026.171480 · Cited by 7
Type‐2 Diabetes, Pancreatic Amylin, and Neuronal Metabolic Remodeling in Alzheimer's Disease
Leibold, N. S., Bain, J. R., & Despa, F. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200405 · Cited by 8
Amylin analogs for the treatment of obesity without diabetes: present and future
Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2409403 · Cited by 5
Ooi, S. A., Valli, D., Kuska, M. I., Marí, H., Chaudhary, H., Wahlgren, W. Y., Westenhoff, S., Tietze, A. A., Novials, A., Servitja, J., et al. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169405 · Cited by 5
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 7
Ludwig, M. Q., Coester, B., Gordian, D., Hassan, S., Tomlinson, A. J., Toure, M. H., Christensen, O. P., Lommi, G., Moltke-Prehn, A., Brown, J. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01539-3 · Cited by 21
Self-citationSun, X., Yang, D., Li, Y., Shi, J., Zhang, X., & Yi, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171203 · Cited by 6
A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics
Jacobsen, M. T., Poulsen, C., Kopp, K. L., Olsen, J., & Cox, N. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch07 · Cited by 5
Self-citationGabery, S., Glendorf, T., Ballarín-González, B., Pedersen, K., Kruse, T., Raun, K., & Kuhre, R. E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123845 · Cited by 4
Self-citationZheng, N., Chen, R., Yang, L., Xu, P., Wang, X., Sun, X., Lin, Y.-X., Qiu, J., Su, X., Wang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02893 · Cited by 4
Gadelmawla, A. F., Hammad, N., Atta, K., Diaa, A., Abouzkaly, F., Soni, K., Kelkar, R., Agrawal, S. P., Ahmed, R., Jain, H., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.030 · Cited by 4
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Modulation of amylin and calcitonin receptor activation by hybrid peptides
Lee, S. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171314 · Cited by 3
Zaykov, A. N., Gelfanov, V. M., Tagmose, T. M., Demozay, D., Manfé, V., Rohlfs, R., Rivir, M., Pérez–Tilve, D., Finan, B., & DiMarchi, R. D. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00078a · Cited by 4
Gu, Y.-M., Yuan, Q., Li, X., He, Q., Xu, H. E., & Zhao, L. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01635-2 · Cited by 4
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
Rao, H., Kumar, S., Ali, S. M. E., Asif, H. M., Kumar, M., Kumar, L., & Raja, A. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01942-3 · Cited by 3
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Gabe, M. B. N., Fuhr, R., Sinn, A., Eliasen, A., Berthelsen, K. K., Kuhlman, A. B., Bækdal, T. A., & Nejad, A. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15951 · Cited by 3
Al‐Horani, R. A., Aliter, K. F., & Aliter, H. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998276832231124170324 · Cited by 5
Cagrilintide Combined with Semaglutide: a new Approach for Treatment of Obesity and type 2 Diabetes
Mikhail, N. (2023) · Clinical Research and Clinical Trials · doi:10.31579/2693-4779/154 · Cited by 3
A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy
Lee, S. M. (2025) · Current Drug Targets · doi:10.2174/0113894501398624250819070004 · Cited by 2
Zhou, Y., Xu, P., Lu, J., Xu, S., Qiu, W., Ning, X., Xu, J., & Zheng, N. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00558 · Cited by 2
Nielsen, M. J. F., Becker, N., Duus, H. H. H., Kirkeby, K., Kupčová, V., Lauenborg, B. W., Low, B., Svolgaard, O., & Witten, L. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01654-0 · Cited by 3
Amylin at the crossroads of type 2 diabetes and neurodegenerative diseases
Castillo, I. L. D., Garcia-Martin, J., Gutiérrez, A., & Moreno‐González, I. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103226 · Cited by 1
Structure, Self-Association, and Aggregation Properties of a Long-Acting Amylin Receptor Agonist
Poulsen, C., Norrman, M., Thomsen, J. K., & Wahlund, P. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00161 · Cited by 2
Self-citationAdvancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
Al-Harbi, F. A., Alsaif, A. K., Almutairi, A. M., Alshehri, H. J., Aleidan, E. A., Alabdulaaly, G. S., Alanazi, M. E., & Azzam, A. Y. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100414 · Cited by 1
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_25 · Cited by 3
Metadata
- Authors
- Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk, Novo Nordisk Park, DK-2760 Maaloev, Denmark
- Corresponding author
- Kruse, Thomas
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-07-21
- Volume
- 64
- Issue
- 15
- Pages
- 11183-11194
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3187035249
- Cited by
- 129
- References
- 42
- Citations by year
- 2026: 27 · 2025: 40 · 2024: 26 · 2023: 19 · 2022: 14 · 2021: 3
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- cagrilintide, amylin analogues, long-acting insulin analogues, obesity, weight loss, semaglutide, GLP-1 receptor agonists, structure-activity relationship, clinical development
- MeSH terms
- Drug Development, Dose-Response Relationship, Drug, Humans, Hypoglycemic Agents, Models, Molecular, Structure-Activity Relationship, Molecular Structure, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.